Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

COMPASS Pathways Plc - American Depository Shares (NQ:CMPS)

14.61 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about COMPASS Pathways Plc - American Depository Shares

< Previous 1 2
...
26 27 28 29 30 31 32 33 Next >
News headline image
This Company Just Extended its Reach into the United Kingdom by Opening its First Ketamine Therapy Clinic ↗
Photo by cottonbro from Pexels The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner... 
Via Benzinga
A.I. Breakthrough Could Disrupt the $11 Trillion Medical Sector
FN Media Group Presents Oilprice.com Market Commentary London – October 18, 2021 – A massive disruption now appears imminent in one of the world’s largest – and most important – industries. In much the... 
Via FinancialNewsMedia
Topics Artificial Intelligence
News headline image
Forget The Hype: The Psychedelic Stocks Sector Went Down In The Third Quarter Of 2021 ↗
Despite the prevailing hype, the psychedelic sector went down considerably last quarter (July through September) and has gone down even further so far this month. 
Via Talk Markets
News headline image
Psychedelic Stocks: Financial Strength, Growth Potential, Compelling Valuations ↗
Blue-chip stocks: grossly inflated valuations and loaded with debt. Psychedelic stocks: lean valuations and loaded with cash. A very attractive option in uncertain markets. 
Via Talk Markets
News headline image
There Are Now 50 Psychedelics Companies Listed In The U.S. - Here They Are ↗
Just two years ago, the psychedelics sector was a small research space reserved for academics and extremely forward-thinking investors. S... 
Via Benzinga
News headline image
Why Compass Pathways Stock Dropped 12% in September ↗
Progress continues on the company's work to develop a mental health treatment using a psychoactive drug therapy. 
Via The Motley Fool
NetworkNewsAudio – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Bringing Therapeutic Options to Diseases with Unmet Needs
Via Investor Brand Network
Topics Cannabis
U.S. Is Dominating Psychedelic Drugs Market Due To Growing Acceptance For Treating Depression & Rise In Product Approvals
Palm Beach, FL –October 12, 2021 – FinancialNewsMedia.com News Commentary – After being relegated to the margins of sincere scientific examination for about the last several decades, growing... 
Via FinancialNewsMedia
Psychedelics Renaissance Underway as Paradigm Shifting Cure for Depression Potentially Discovered
Via FinancialNewsMedia
Topics Law Enforcement
Investors Turning to Psychedelic Market as Renaissance Continues into New Wave of Diseases
Via Investor Brand Network
Topics Cannabis
Strong Pipeline of Drugs for Treatment Of Psychotic Disorders Anticipated To Drive The Market Through 2028
Palm Beach, FL –October 11, 2021 – FinancialNewsMedia.com News Commentary – There is a high demand for more advanced products for the treatment and maintenance of severe mental disorders. Thus,... 
Via FinancialNewsMedia
News headline image
1 Recent Healthcare IPO to Put on Your Radar ↗
Here's a pharmaceutical company that could have an incredibly bright future. 
Via The Motley Fool
Topics Initial Public Offering
News headline image
Is Ketamine A Psychedelic? Depends On Who You Ask ↗
Ketamine, an FDA-approved anesthetic drug, has recently become the star of the psychedelic medicine movement. As p... 
Via Benzinga
Why North America Region is Dominating the Billion Dollar Psychedelic Drugs Market
Palm Beach, FL – October 5, 2021 – FinancialNewsMedia.com News Commentary – The psychedelic drugs market is creating major potential for treatment of mental illnesses, and as a result, it is likely to... 
Via FinancialNewsMedia
Senate Bill Decriminalizing Psychedelics Could Help Reverse Some “War on Drugs” Impacts
Via FinancialNewsMedia
News headline image
The Three Psychedelics ETFs: Which Is The Best Fit For Your Portfolio? ↗
We compare and contrast the three psychedelic drug ETFs and assess which investor needs each addresses. 
Via Talk Markets
News headline image
Psyched: First Active Psychedelics ETF Hits NYSE, Compass Dives Into Novel Molecules, Atai Subsidiary Launches Phase 2a Trial ↗
AdvisorShares Launches First NYSE-listed Actively-managed Psychedelics ETF On Thursday, AdvisorShares 
Via Benzinga
News headline image
Which Psychedelic Stock ETF Is Right For You? ↗
This week the AdvisorShares Psychedelics ETF began trading on the NYSE Arca. Here we compare the make-up of the now 3 psychedelic stock ETFs and two tracking indexes. 
Via Talk Markets
News headline image
Compass: Psychedelics Unicorn Expands Portfolio Beyond Psilocybin Into Psychedelics 2.0 ↗
Psychedelics biotech company Compass Pathways (NASDAQ:CMPS... 
Via Benzinga
News headline image
Psychedelic Medicine's Top CEOs: Who's Running The Biggest Companies In This Booming Industry? ↗
By Natan Ponieman and Javier Hasse The psychedelic medicine industry is growing by leaps and bounds. Leading this charge is a group of ambitious and visionary corporate... 
Via Benzinga
National Suicide Prevention Week Shines Light on Psychedelic Treatments
Via FinancialNewsMedia
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
Gainers Cardiff Oncology (NASDAQ: 
Via Benzinga
News headline image
3 Biotech Stocks Wall Street Expects to Double Soon ↗
All three stocks on this list can more than double your money according to investment bank analysts who cover them. 
Via The Motley Fool
News headline image
Psychedelic Drug Industry Report Card For 2021 ↗
In assessing the psychedelic drug industry, a primary focus for investors is drug development. 
Via Talk Markets
News headline image
Magic Mushroom Drug Stock Performances YTD ↗
Of the 35 companies involved in clinical stage research of psychedelic substances, 20 are researching the benefits of psilocybin, the primary psychoactive ingredient in “magic mushrooms”. 
Via Talk Markets
News headline image
Braxia Scientific Launches Broad Criteria Trial On Psilocybin For Depression ↗
Braxia Scientific Corp. (CSE:BRAX) (OTC: 
Via Benzinga
News headline image
Open-Minded? Buy This Game-Changing Psychedelics Stock Now ↗
Excellent investing opportunities frequently seem outlandish. 
Via The Motley Fool
Topics Supply Chain
News headline image
Psychedelic Drug Patents: All Patents Are Not Created Equal ↗
With many drug patenting opportunities in the emerging psychedelic drug industry, investors need to get up-to-speed on the different types of patents available -- and their strengths and weaknesses. 
Via Talk Markets
Topics Intellectual Property
News headline image
3 Disruptive Mental Health Stocks to Consider Buying Before They're Huge ↗
They're the first pioneers in exciting new markets. 
Via The Motley Fool
News headline image
Compass Pathways Q2 Financials: Net Profit Down -38%; Stock Down -59% YTD ↗
COMPASS Pathways plc reported its financial results for the Q2 ending June 30th, 2021, today, and gave an update on recent progress across its business. 
Via Talk Markets
< Previous 1 2
...
26 27 28 29 30 31 32 33 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.